Moderna and Merck Vaccine Cuts Melanoma Recurrence Risk by 42%
The personalized vaccine cut melanoma recurrence or death by 42% and left 82% of patients cancer-free at two years, researchers said.
- On Friday, an Australian-led Phase 3 trial revealed that adding a personalized mRNA vaccine to immunotherapy reduced melanoma recurrence or death risk by 42 per cent. Principal Investigator Professor Georgina Long will present findings this weekend.
- Known as intismeran, the vaccine creates a unique 'fingerprint' from each patient's tumor by comparing mutations to healthy cells. This teaches the immune system to recognize and destroy distinct cancer cells.
- The trial involved 1,137 patients across 157 sites worldwide who had undergone surgery. At two years, 82 per cent receiving combined treatment were melanoma-free, compared with 70 per cent on immunotherapy alone.
- Melanoma Institute Australia confirmed the treatment is not yet available, facing a multi-year regulatory review process. Long called the results a 'foundational shift' in how the immune system targets cancer.
- Experts emphasize the vaccine is not preventative and requires further study before broader use. Researchers now aim to determine whether reduced recurrence translates into longer survival for high-risk melanoma patients.
170 Articles
170 Articles
A unique cancer vaccine significantly reduces the risk of recurrence in patients with melanoma, according to the results of a major study published on Thursday by the pharmaceutical laboratories Moderna and Merck.
American pharmaceutical companies Moderna and Merck have developed a vaccine that could represent a breakthrough in the treatment of skin cancer. It is a personalized vaccine based on an mRNA molecule that teaches the immune system to recognize the causative agent of the disease and create a defensive response.
WaPo: Melanoma Vaccine Trial Shows Great Promise
The Washington Post reports: A groundbreaking vaccine reduced the risk of death or recurrence of melanoma by almost half, an encouraging signal for a treatment seeking federal approval that has boosted the fortunes of drugmakers Moderna and Merck and could usher in a new wave of cancer treatments. The drug, intismeran autogene, which uses messenger … The post WaPo: Melanoma Vaccine Trial Shows Great Promise appeared first on Joe.My.God..
Moderna and Merck announce positive results against melanoma in phase III trial, with more than 1,100 patients
A personalized mRNA vaccine shows success in black skin cancer in studies. The risk of relapse or death decreases significantly.
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
